GlassScriptPhysician profile
Eleanor E Hess
NPI 1982607099
$9,086.02
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,704 · 2022: $2,190 · 2023: $3,339 · 2024: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,049.03 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $863.81 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $778.72 | 2021-2024 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $670.73 | 2021-2024 | Xarelto, Spravato |
| Abbvie INC. | $578.89 | 2021-2024 | |
| Pfizer INC. | $534.79 | 2021-2024 | |
| Astellas Pharma US INC | $437.26 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.49 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $375.88 | 2021-2024 | |
| Glaxosmithkline, LLC. | $367.55 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $301.33 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $260.18 | 2021-2024 | Aralast, Trintellix |
| Novartis Pharmaceuticals Corporation | $241.94 | 2021-2024 | |
| Abbott Laboratories | $231.60 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $203.31 | 2021-2024 | Otezla, Repatha |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.